Literature DB >> 33799903

Genetic Association of Hepatitis C-Related Mixed Cryoglobulinemia: A 10-Year Prospective Study of Asians Treated with Antivirals.

Ming-Ling Chang1,2, Su-Wei Chang3,4, Shiang-Chi Chen5, Rong-Nan Chien1,2, Chia-Lin Hsu6, Ming-Yu Chang2,7,8, Cathy S J Fann6.   

Abstract

Genetic profiles of hepatitis C virus (HCV)-associated mixed cryoglobulinemia (MC) in Asians remain elusive. A 10-year prospective cohort study was conducted with 1043 consecutive HCV Ab-positive Taiwanese surveyed with 13 single nucleotide polymorphisms (SNPs). Of 1043, 589 (56.5%) had baseline MC, 934 (89.5%) had positive HCV RNA, 796 completed anti-HCV therapy, and 715 had sustained virological responses (SVRs). SNP associations were surveyed withgenotypic, allelic, trend, permutation and multivariate analyses. At baseline, higher male sex and MC rates were noted in HCV RNA-positive than RNA-negative patients; higher female sex and positive HCV RNA rates but lower HCV RNA levels were noted in patients with than those without MC. Baseline associations were: HLA II-rs9461776 A allele, IFNL3-rs12979860 T allele, SERPINE1-rs6976053 C allele and MC with HCV RNA positivity; IFNL3-rs12979860 C allele, ARNTL-rs6486122 T allele and HCV RNA positivity with baseline MC. In SVR patients, RETN-rs1423096 C allele and SERPINE1-rs6976053 T allele were associated with 24-week and 10-year post-therapy MC, respectively. Conclusions: HCV RNA, IFNL3-rs12979860 and ARNTL-rs6486122 were associated with baseline MC; RETN-rs1423096 and SERPINE1-rs6976053 were associated with short- and long-term post-therapy MC in SVR patients, respectively. Links with HCV RNA and immune-associated SNPs suggest MC an immune reaction to expel HCV.

Entities:  

Keywords:  ARNTL; HCV; IFNL3; PAI-1; mixed cryoglobulinemia

Year:  2021        PMID: 33799903      PMCID: PMC7998980          DOI: 10.3390/v13030464

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  38 in total

1.  Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinaemia: an 8-year prospective study.

Authors:  Y-T Cheng; J-S Cheng; C-H Lin; T-H Chen; K-C Lee; M-L Chang
Journal:  Clin Microbiol Infect       Date:  2019-06-20       Impact factor: 8.067

2.  Protease nexin-1, tPA, and PAI-1 are upregulated in cryoglobulinemic membranoproliferative glomerulonephritis.

Authors:  Sekiko Taneda; Kelly L Hudkins; Anja S Mühlfeld; Jolanta Kowalewska; Jeffrey W Pippin; Stuart J Shankland; Charles E Alpers
Journal:  J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 10.121

3.  Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.

Authors:  Lucio Boglione; Jessica Cusato; Sarah Allegra; Giuseppe Cariti; Giovanni Di Perri; Antonio D'Avolio
Journal:  Arch Virol       Date:  2015-06-10       Impact factor: 2.574

4.  Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.

Authors:  Laura Gragnani; Marcella Visentini; Elisa Fognani; Teresa Urraro; Adriano De Santis; Luisa Petraccia; Marie Perez; Giorgia Ceccotti; Stefania Colantuono; Milica Mitrevski; Cristina Stasi; Martina Del Padre; Monica Monti; Elena Gianni; Alessandro Pulsoni; Massimo Fiorilli; Milvia Casato; Anna Linda Zignego
Journal:  Hepatology       Date:  2016-08-29       Impact factor: 17.425

5.  Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.

Authors:  Sergio M Borgia; Charlotte Hedskog; Bandita Parhy; Robert H Hyland; Luisa M Stamm; Diana M Brainard; Mani G Subramanian; John G McHutchison; Hongmei Mo; Evguenia Svarovskaia; Stephen D Shafran
Journal:  J Infect Dis       Date:  2018-10-20       Impact factor: 5.226

6.  Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study.

Authors:  A Piluso; C Giannini; E Fognani; L Gragnani; P Caini; M Monti; A Petrarca; J Ranieri; T Urraro; E Triboli; G Laffi; A L Zignego
Journal:  J Viral Hepat       Date:  2012-12-04       Impact factor: 3.728

7.  Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance.

Authors:  Ming-Ling Chang; Yu-Sheng Lin; Li-Heng Pao; Hsin-Chih Huang; Cheng-Tang Chiu
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

8.  Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases.

Authors:  Laura Gragnani; Elisa Fognani; Valli De Re; Massimo Libra; Adriana Garozzo; Patrizio Caini; Guia Cerretelli; Andrea Giovannelli; Serena Lorini; Monica Monti; Silvia Bagnoli; Irene Piaceri; Anna Linda Zignego
Journal:  Oncotarget       Date:  2017-05-06

9.  Association of variants in RETN with plasma resistin levels and diabetes-related traits in the Framingham Offspring Study.

Authors:  Marie-France Hivert; Alisa K Manning; Jarred B McAteer; Josée Dupuis; Caroline S Fox; L Adrienne Cupples; James B Meigs; Jose C Florez
Journal:  Diabetes       Date:  2008-12-15       Impact factor: 9.461

10.  Predicting HLA genotypes using unphased and flanking single-nucleotide polymorphisms in Han Chinese population.

Authors:  Ai-Ru Hsieh; Su-Wei Chang; Pei-Lung Chen; Chen-Chung Chu; Ching-Lin Hsiao; Wei-Shiung Yang; Chien-Ching Chang; Jer-Yuarn Wu; Yuan-Tsong Chen; Tien-Chun Chang; Cathy Sj Fann
Journal:  BMC Genomics       Date:  2014-01-29       Impact factor: 3.969

View more
  2 in total

Review 1.  Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure.

Authors:  Mahmood Danishwar; Zahid Jamil; Salman Khan; Michael Nakhla; Ishtiaq Ahmad; Muhammad Ashar Ali; Daryl T Y Lau
Journal:  J Clin Med       Date:  2022-02-14       Impact factor: 4.241

2.  Hepatitis C Virus Reactivation in Anti-HCV Antibody-Positive Patients with Chronic Hepatitis B Following Anti-HBV Therapies.

Authors:  Yi-Tse Su; Ming-Ling Chang; Rong-Nan Chien; Yun-Fan Liaw
Journal:  Viruses       Date:  2022-08-24       Impact factor: 5.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.